Zanubrutinib was also evaluated in combination with venetoclax in patients with previously untreated CLL with del(17p) and/or TP53 mutation in the SEQUOIA trial arm D. Patients were 65 years old or between 18 and 64 years with comorbidities. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.